$HALB News

Last published 4y ago

4y agoHALBHalberd Medical Breakthrough for the Treatment of Neurodegenerative Diseases Affecting 36 Million Americans AnnuallyACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / February 22, 2022 / Halberd Corporation (OTC:HALB) has made a medical breakthrough in the treatment of neurodegenerative diseases. With the successful elimination of glutamate from cerebral spinal fluid (CSF), Halberd ha
4y agoHALBHalberd Eliminates 100% of Tau Protein From CSF - The 9th of 10 Target Neurodegenerative Disease AntigensACCESS NewswireTau buildup in the brain is linked to Alzheimer's and other neurodegenerative diseases. JACKSON CENTER, PA / ACCESSWIRE / February 8, 2022 / Halberd Corporation (OTC:HALB) has demonstrated the ability to eliminate 100% of Tau protein from cerebral spina
4y agoHALBHalberd Achieves Landmark Selective Elimination of Tau From an Antigen MixtureACCESS NewswireTau has been shown to be important in the development of Alzheimer's Disease. Eradication of Tau accomplished without reducing levels of non-target cytokine. JACKSON CENTER, PA / ACCESSWIRE / February 1, 2022 / Halberd Corporation (OTC:HALB) has demons
4y agoHALBHalberd CEO Letter: 2021 Year-End & 2022 OutlookACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / January 25, 2022 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC:HALB) First of all I want to wish all of our shareholders and constituents a Very Healthy, Happy and Prosperous New Year! 2021 OVERVIEW A
4y agoHALBHalberd, Inc. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative DiseasesACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / January 13, 2022 / Halberd, Inc. (OTC:HALB) ("HALB" or the "Company"), an innovative biotech company focused on developing treatments for difficult-to-cure debilitating diseases, today announces that they have been able
4y agoHALBHalberd Corporation Now an Official US Government ContractorACCESS NewswireHalberd to bid on Additional Federal Contracts with the Federal Government JACKSON CENTER, PA / ACCESSWIRE / January 5, 2022 / Halberd Corporation (OTC:HALB) is now registered with the Federal Government's System for Award Management allowing Halberd to
4y agoHALBHalberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative DiseasesACCESS NewswireLatest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid JACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation (OTC:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CS
4y agoHALBHalberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative DiseasesACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / December 15, 2021 / Halberd Corporation (OTC:HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-12 is a pro-inflammatory cytok
4y agoHALBHalberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative DiseasesACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / December 13, 2021 / Halberd Corporation (OTC:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous di
4y agoHALBHalberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer's Disease and PTSD/CTEACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / December 6, 2021 / Halberd Corporation (OTC:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF). These tests confirmed virtually 100% el
4y agoHALBHalberd Successfully Eradicates TNF-a, a Major Contributing Factor to Alzheimer's DiseaseACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / November 22, 2021 / Halberd Corporation (OTC:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Through Halberd's patented extraco
5y agoHALBHalberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency WavesACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / November 8, 2021 / Halberd Corporation (OTC:HALB) filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves. Previously, Halberd filed a provisional
5y agoGTXO HALBGTX Corp Begins Selling Vita-Shield-Max Immune Support NutraceuticalGlobeNewswireLOS ANGELES CALIFORNIA, Nov. 02, 2021 (GLOBE NEWSWIRE) -- GTX Corp (OTC:GTXO) ("the Company"), a pioneer in the fields of: health & safety wearable GPS human and asset tracking systems and personal protective medical equipment and supplies, today annou
5y agoHALBHalberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer's DiseaseACCESS NewswireElevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer's Disease. JACKSON CENTER, PA / ACCESSWIRE / November 1, 2021 / Halberd Corporation (OTC:HALB) successfully eradicated 100% of IL-6 from syn
5y agoHALBHalberd Files Provisional Patent on Breakthrough Obesity TreatmentACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / October 25, 2021 / Halberd Corporation (OTC:HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the v
5y agoHALBHalberd's PTSD/Alzheimer's R&D Reveals Link to Potential Obesity CureACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / October 20, 2021 / Halberd Corporation's (OTC:HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer's Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle
5y agoGTXO HALBHalberd and GTX Corp. Sign Scientific Collaboration and Reseller AgreementACCESS NewswireGTX and Halberd will begin collaborating on developing and testing treatments for Alzheimer's Disease/PTSD and other neurological diseases and GTX will begin marketing Halberd's VitaShieldMaxTM Immune Support through their online ecommerce platform. JAC
5y agoHALBHalberd Corporation CEO LetterACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / October 7, 2021 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC:HALB) This past quarter, Halberd has made some very significant and unparalleled achievements developing treatments for neurodegenerative
5y agoHALBHalberd's VITASHIELDMAX(TM) Immunity Support Product Available on AmazonACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / October 5, 2021 / Halberd Corporation (OTC:HALB) announced that its nutraceutical immune support product, VitaShieldMaxTM, is now available through Amazon, in addition to its availability through Halberd's website at www
5y agoHALB RSHNHalberd and heliosDX of RushNet Enter Scientific Collaboration AgreementACCESS NewswireAgreement To Advance Healthcare Diagnostic Technologies JACKSON CENTER, PA / ACCESSWIRE / September 22, 2021 / Halberd Corp. (OTC:HALB) and heliosDx, a wholly owned company of RushNet, Inc. (OTC:RSHN), an Alpharetta, GA company, announce a Scientific Co
5y agoHALBHalberd's Treatment Eradicates Primary Building Block of Alzheimer's DiseaseACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / September 13, 2021 / Halberd Corporation (OTC:HALB) has successfully eradicated the primary building block of neurofibrillary tangles of Alzheimer's Disease from test fluids in laboratory testing. Through its patented ex
5y agoHALBHalberd Corporation Appoints Anthony Mirabelli Vice-President, Mergers & AcquisitionsACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / September 8, 2021 / Halberd Corporation (OTC:HALB) announced the appointment of Anthony Mirabelli to the position of Vice-President, Mergers & Acquisitions. Mirabelli will be responsible for negotiating joint ventures, l
5y agoHALBHalberd Corporation Alzheimer's Disease Treatment Tests Yield Outstanding ResultsACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / August 30, 2021 / Halberd Corp. (OTC:HALB) provided an update on its Alzheimer's Disease eradication experimentation being conducted at Youngstown State University (YSU) and Arizona State University (ASU). Following stan
5y agoHALBHalberd Receives Patent for Treatment of Cockayne Syndrome - May Provide Pathway to Slow AgingACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / August 25, 2021 / Halberd Corporation (OTC:HALB) received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office, for the treatment of Cockayne Syndrome. Cockayne Syndrome
5y agoHALBHalberd Files Provisional Patent Application - Furthering Efforts on Alzheimer's DiseaseACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / August 23, 2021 / Halberd Corp. (OTC:HALB) announced filing a U. S. joint provisional patent application, "Treating Alzheimer's Disease Utilizing Extracorporeal Radio Frequency." The innovation is a result of Halberd's S
5y agoHALBHalberd Corp. VITA-SHIELD-MAX(TM) Available - Buy Now!ACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / August 18, 2021 / Halberd Corporation's (OTC:HALB) Nutraceutical product, Vita-Shield-MaxTM is now available on www.vitashieldmax.com. Vita-Shield-MaxTM is a specially formulated Nutraceutical to help maintain a healthy
5y agoHALBHalberd's Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBNACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / August 16, 2021 / Halberd Corporation's (OTC:HALB) research at Youngstown State University (YSU) caught the attention of Youngstown, OH TV news station, WKBN, a CBS affiliate. The station's 5:00PM newscast on Friday, Aug
5y agoHALBHalberd Corporation Adds Blood-Borne Disease Treatment Capability With Addition Of Noted NephrologistACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / August 11, 2021 / Halberd Corporation (OTC:HALB) today confirmed the addition of Dr. Ned Kronfol as a member of its Scientific Advisory Board. Dr. Kronfol is certified by the American Board of Internal Medicine and retir
5y agoHALBHalberd Corporation's VITA-SHIELD-MAX(TM) Immunity Support Product ShippedACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / August 9, 2021 / Halberd Corporation (OTC:HALB) reports Vita-Shield-MaxTM, has been shipped! With Covid-19 cases back on the rise fueled by the Delta Variant, this "Immunity Support Nutraceutical Product" is arriving at
5y agoHALBHalberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept - "Never Before Accomplished"ACCESS NewswireA Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer's Disease/PTSD/CTE JACKSON CENTER, PA / ACCESSWIRE / July 28, 2021 / Halberd Corporation (OTC:HALB) establishes "proof of concept" taking a major s
5y agoHALBHalberd Corp. Advances the Elimination of Antigens Present in Alzheimer's Disease & PTSD/Chronic Traumatic EncephalopathyACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / July 22, 2021 / Halberd Corporation (OTC:HALB) confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer's Disease (AD) antibodies, Tau and Phosphorylated Tau. Having successfully conjugated the
5y agoHALBHalberd Corporation CEO LetterACCESS NewswireQ2-21 Accomplishments and Q3 Plans JACKSON CENTER, PA / ACCESSWIRE / July 6, 2021 / Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC:HALB) As we began the second quarter, the company, along with the rest of the country, was focused on devel
5y agoHALBHalberd Corp. Discovers a Proprietary Disease-Causing Antigen Removal ProcessACCESS NewswireMethod Does Not Require Antibody Conjugated Metallic Nanoparticles JACKSON CENTER, PA / ACCESSWIRE / June 30, 2021 / Halberd Corporation (OTC:HALB) announces a possible breakthrough method for the removal of the disease-causing antigen(s) that does not
5y agoHALBHalberd Corporation's Proprietary Technology for Alzheimer's Disease Enters Stage 4 of 7 Stage ProcessACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / June 21, 2021 / Halberd Corporation's (OTC:HALB) proprietary technology enters stage 4 to address Alzheimer's Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency wa
5y agoHALBHalberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer's Disease-Associated AntigensACCESS NewswireEnables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy JACKSON CENTER, PA / ACCESSWIRE / June 16, 2021 / Halberd Corporation (OTC:HALB) has successfully conjugated, Tau, Phosphorylated
5y agoHALBHalberd Corporation Undertakes Process Toward the Elimination of Alzheimer's DiseaseACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / June 9, 2021 / Halberd Corporation (OTC:HALB) commences experimentations to eradicate three of the principal components of Alzheimer's Disease. By eliminating these three critical antigens, which form the basis for neuro
5y agoHALBHalberd Corporation Creates Two New and Stronger SARS-CoV-2 Neutralizing AntibodiesACCESS NewswireDemonstrates Greater Binding Affinity Than Previous Antibodies JACKSON CENTER, PA / ACCESSWIRE / June 7, 2021 / Halberd Corporation (OTC:HALB) announces the successful creation of two new neutralizing antibodies against the Spike Protein of SARS-CoV-2,
5y agoHALBHalberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser ProjectsACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / June 1, 2021 / Halberd Corporation (OTC:HALB) announced the filing of a U. S. joint provisional patent application titled, "Antibody Conjugated Nanoparticle Assay And Treatment For SARS-CoV-2." The innovation is a resul
5y agoHALBHalberd Corporation Successfully Conjugates Metallic Particles and E. Coli AntibodyACCESS NewswireBreakthrough Achievement Enables Extracorporeal Eradication of Pathogens Via Radio Frequency Waves and/or Laser Emissive Energy JACKSON CENTER, PA / ACCESSWIRE / May 25, 2021 / Halberd Corporation (OTC:HALB) announces the successful conjugation of gold-
5y agoHALB"MarketWatch" Features Halberd Corporation With Prominent Pharmaceutical Companies on New Treatments for COVID-19ACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / May 19, 2021 / Halberd Corporation (OTC:HALB) was featured in a recent MarketWatch article, "New Approaches to Covid-19 Treatment Enter the Picture," along with six other notable biotechnology companies. As stated in the
5y agoHALBHalberd Corporation Reports Successful Conjugation of Metallic Particles & SARS-CoV-2 Proprietary Monoclonal AntibodyACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / May 17, 2021 / Halberd Corporation (OTC:HALB) announces the successful conjugation of gold-coated iron nanoparticles with Halberd's patent-pending monoclonal antibody against the SARS-CoV-2 spike protein. This milestone
5y agoHALBHalberd Corporation Begins Testing of Patented Process for Laser Eradication of DiseaseACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / May 13, 2021 / Halberd Corporation (OTC:HALB) announces the commencement of its patented extra-corporeal process experimentation using lasers to eradicate disease. This technology facilitates disease eradication without
5y agoHALBHalberd Corp. Designated as a BREAKOUT Stock to Watch in Investor PublicationsACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / May 10, 2021 / Halberd Corporation (OTC:HALB) was recently discussed in Penny Stocks News and Wall Street Trader publications as a BREAKOUT stock to watch with a projected share price of HALB to rise above the $0.06/shar
5y agoHALBHalberd Corporation Appoints New Chief Technical Officer to Optimize Upcoming Experiments On Radio Frequency and Laser Eradication of DiseaseACCESS NewswireJACKSON CENTER, PA / ACCESSWIRE / May 4, 2021 / Halberd Corporation (OTC:HALB) announces the appointment of Dr. Mitchell S. Felder, previously a consultant to Halberd Corporation, to the position of Chief Technical Officer. Dr. Patricio Reyes, former Chi